跳至主要内容
临床试验/DRKS00009316
DRKS00009316已完成不适用

on-intervention study to the capture of the quality of life with the adult patients who receive Akynzeo to the prevention from nausea and vomiting caused by highly or moderate emetogenic chemotherapy - AkyPro NIS

RIEMSER Pharma GmbH0 个研究点目标入组 2,173 人开始时间: 2015年10月20日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
2,173

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Signed patient consent form
  • Age: = 18 Years
  • 1- or 2-day chemotherapy, high or moderate emetogen
  • anti-emetic prevention with Akynzeo® according to the summary of product characteristics

排除标准

  • Patients without chemotherapy
  • radiotherapy alone
  • brain tumour, symptomatic brain metastases
  • anticipatory nausea and vomiting
  • not chemotherapy-induced nausea and vomiting on the basis of other disorders or drugs
  • chemotherapies that last more than 2 days within a chemotherapy cycle
  • pregnancy
  • hypersensitivity to the active substances, excipient or other constituent materials of Akynzeo®

研究者

相似试验